These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16028487)

  • 1. Efficacies of liposome-encapsulated enrofloxacin against Staphylococcus aureus infection in Anatolian shepherd dog monocytes in vitro.
    Baş AL; Simşek A; Erganiş O; Corlu M
    Dtsch Tierarztl Wochenschr; 2005 Jun; 112(6):219-23. PubMed ID: 16028487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of liposomal enrofloxacin for intracellular infections in Kangal dogs and visualization of phagocytosis of liposomes.
    Deĝim Z; Deĝim T; Bas L; Elmas M
    J Biomed Mater Res; 2002 Aug; 61(2):246-51. PubMed ID: 12007205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of intracellular concentrations of free and two types of liposome-encapsulated enrofloxacin in anatolian shepherd dog monocytes.
    Baş LA; Simşek A; Corlu M; Yazar E; Elmas M; Değim ZG
    J Vet Med B Infect Dis Vet Public Health; 2002 Aug; 49(6):289-93. PubMed ID: 12241030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained release of liposome-encapsulated enrofloxacin after intramuscular administration in rabbits.
    Cabanes A; Reig F; Antón JM; Arboix M
    Am J Vet Res; 1995 Nov; 56(11):1498-501. PubMed ID: 8585663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylcoccus aureus by murine macrophages.
    Wong JP; Schnell G; Simpson M; Saravolac E
    Artif Cells Blood Substit Immobil Biotechnol; 2000 Sep; 28(5):415-28. PubMed ID: 11009114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.
    Meinen JB; McClure JT; Rosin E
    Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
    Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
    Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococci surviving intracellularly in phagocytes from patients suffering from chronic granulomatous disease are killed in vitro by antibiotics encapsulated in liposomes.
    Roesler J; Hockertz S; Vogt B; Lohmann-Matthes ML
    J Clin Invest; 1991 Oct; 88(4):1224-9. PubMed ID: 1918376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
    Cole LK; Papich MG; Kwochka KW; Hillier A; Smeak DD; Lehman AM
    Vet Dermatol; 2009 Feb; 20(1):51-9. PubMed ID: 19152587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa.
    Cole LK; Kwochka KW; Hillier A; Kowalski JJ; Smeak DD; Kelbick NT
    Vet Dermatol; 2006 Apr; 17(2):128-33. PubMed ID: 16515655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative quantification of the in vitro activity of veterinary fluoroquinolones.
    Grobbel M; Lübke-Becker A; Wieler LH; Froyman R; Friederichs S; Filios S
    Vet Microbiol; 2007 Sep; 124(1-2):73-81. PubMed ID: 17498893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
    Nguyen HA; Grellet J; Dubois V; Saux MC; Quentin C
    J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
    Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
    J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of skin concentrations of enrofloxacin in dogs with pyoderma.
    DeManuelle TC; Ihrke PJ; Brandt CM; Kass PH; Vulliet PR
    Am J Vet Res; 1998 Dec; 59(12):1599-604. PubMed ID: 9858413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.
    Ganière JP; Médaille C; Limet A; Ruvoen N; André-Fontaine G
    Vet Dermatol; 2001 Jun; 12(3):171-5. PubMed ID: 11420933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome combined porous beta-TCP scaffold: preparation, characterization, and anti-biofilm activity.
    Zhu CT; Xu YQ; Shi J; Li J; Ding J
    Drug Deliv; 2010 Aug; 17(6):391-8. PubMed ID: 20429845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of enrofloxacin-loaded MLV liposomes.
    Sezer AD; Akbuğa J; Baş AL
    Drug Deliv; 2007 Jan; 14(1):47-53. PubMed ID: 17107930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of clindamycin in the treatment of Staphylococcus aureus osteomyelitis in dogs.
    Braden TD; Johnson CA; Wakenell P; Tvedten HW; Mostosky UV
    J Am Vet Med Assoc; 1988 Jun; 192(12):1721-5. PubMed ID: 3410788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.